Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2013
08/29/2013WO2013124381A1 Peltatin for use in the treatment of metabolic disorders
08/29/2013WO2013124380A1 Peltatin for the treatment of chronic inflammatory disorders
08/29/2013WO2013124341A1 Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments
08/29/2013WO2013124340A1 Oral pharmaceutical compositions of dabigatran etexilate
08/29/2013WO2013124335A1 Antiviral compounds
08/29/2013WO2013124316A1 Substituted benzothienyl-pyrrolotriazines and uses thereof
08/29/2013WO2013124297A1 Combination of hb-egf binding protein and egfr inhibitor
08/29/2013WO2013124169A1 Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
08/29/2013WO2013124158A1 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
08/29/2013WO2013124068A1 Combinations of albumin-based drug delivery systems
08/29/2013WO2013124026A1 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
08/29/2013WO2013124025A1 Furopyridine derivatives
08/29/2013WO2013123996A1 Novel sirna inhibitors of human icam-1
08/29/2013WO2013123974A1 New inhibitors of influenza a and b viruses acting by disrupting pa and pb1 subunit interactions of heterotrimeric viral rna polymerase
08/29/2013WO2013123965A1 A fixed dose pharmaceutical formulation
08/29/2013WO2013123618A1 Process for manufacture of extract containing zeaxanthin and/or its esters
08/29/2013WO2013123595A1 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
08/29/2013WO2013123588A1 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
08/29/2013WO2013123574A1 Orally bioavailable derivatives of d-gamma-glutamyl-d-tryptophan
08/29/2013WO2013123569A1 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
08/29/2013WO2013102144A8 Ph20 polypeptide variants, formulations and uses thereof
08/29/2013WO2013083225A8 Glucuronolactone derivates as self-tanning substances
08/29/2013WO2012106551A9 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
08/29/2013WO2011084991A3 Fluorinated hdac inhibitors and uses thereof
08/29/2013US20130227717 Hdac inhibitors to treat charcot-marie-tooth disease
08/29/2013US20130226133 Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system
08/29/2013US20130225694 Compositions and methods of inhibiting retinal degeneration
08/29/2013US20130225692 Formulations comprising polyethylene glycol
08/29/2013US20130225690 Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
08/29/2013US20130225689 Pharmaceutical compositions of curcumin
08/29/2013US20130225688 Compositions and methods for the treatment of somatosensory disorders
08/29/2013US20130225685 Combination composition
08/29/2013US20130225684 Methods and compositions for enhancement of vision performance
08/29/2013US20130225683 Compounds and Pharmaceutical Compositions for Uses in Diabetes
08/29/2013US20130225682 Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism II
08/29/2013US20130225678 Therapeutic compositions
08/29/2013US20130225677 Therapeutic compositions
08/29/2013US20130225676 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component
08/29/2013US20130225674 Use of dibenzofuranone derivatives to inhibit kinases
08/29/2013US20130225671 Methods of Treating Seizure Disorders
08/29/2013US20130225670 Methods of Treating Asthma Using Statins
08/29/2013US20130225665 Micrornas that regulate muscle cell proliferation and differentiation
08/29/2013US20130225661 Inhibitors Of SP140 And Their Use In Therapy
08/29/2013US20130225658 Micrornas that regulate muscle cell proliferation and differentiation
08/29/2013US20130225657 SiRNA TARGETING ETS1 AND ELK1 AND METHOD OF USING SAME IN THE INHIBITION OF CIP2A GENE IN CANCER TREATMENT
08/29/2013US20130225655 Combinations of TGFBeta and COX-2 Inhibitors and Methods for Their Therapeutic Application
08/29/2013US20130225653 Microrna-based short hairpin rna for gene knockdown of nr1 subunit of n-methyl-d-aspartate receptor and its application on pharmaceutics
08/29/2013US20130225651 siRNA Compositions and Methods for Potently Inhibiting Viral Infection
08/29/2013US20130225650 Method for promoting synthesis of tissue collagen
08/29/2013US20130225647 Combination therapy with parp inhibitors
08/29/2013US20130225646 Substituted n-phenethyltriazoloneacetamides and use thereof
08/29/2013US20130225643 Endogeneous repair factor production accelerators
08/29/2013US20130225642 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
08/29/2013US20130225640 Cyanoacrylate-based bio-adhesive composition
08/29/2013US20130225639 Altering pharmacokinetics of pirfenidone therapy
08/29/2013US20130225634 Anti-cancer compounds
08/29/2013US20130225631 Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
08/29/2013US20130225630 Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
08/29/2013US20130225629 Targeting pi3k/mtor signalling and neutrophil recruitment for treatment of enteritis
08/29/2013US20130225628 Carboxamide bioisosteres of opiates
08/29/2013US20130225627 Dextromethorphan antitussive compositions
08/29/2013US20130225626 Sublingual films
08/29/2013US20130225623 Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
08/29/2013US20130225620 Serine/threonine kinase inhibitors
08/29/2013US20130225618 Agent for inhibiting expression of lipid metabolism related mrna
08/29/2013US20130225616 Crystalline form of pyrimidio[6,1-a] isoquinolin-4-one compound
08/29/2013US20130225615 2-cycloquinazoline derivatives and methods of use thereof
08/29/2013US20130225614 4-azolylaminoquinazoline derivatives and methods of use thereof
08/29/2013US20130225609 Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists
08/29/2013US20130225607 Method for treating a pulmonary hypertension condition without companion diagnosis
08/29/2013US20130225605 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
08/29/2013US20130225604 Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
08/29/2013US20130225603 Mdm2 inhibitors for treatment of ocular conditions
08/29/2013US20130225599 Novel pyrrolidine derived beta 3 adrenergic receptor agonists
08/29/2013US20130225598 Stabilized Amorphous Forms of Imatinib Mesylate
08/29/2013US20130225597 Use of phosphodiesterase inhibitor to enhance post-surgical erection in men undergoing radical prostatectomy
08/29/2013US20130225595 Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
08/29/2013US20130225590 Substituted triazolo-pyridazine derivatives
08/29/2013US20130225586 Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
08/29/2013US20130225582 Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
08/29/2013US20130225580 Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides
08/29/2013US20130225578 7-cyclylquinazoline derivatives and methods of use thereof
08/29/2013US20130225575 Methods for treating neurological conditions
08/29/2013US20130225574 Oxazolidin-2-one compounds and uses thereof
08/29/2013US20130225570 Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
08/29/2013US20130225569 Furopyridine derivatives
08/29/2013US20130225568 Triazolopyrazine derivatives
08/29/2013US20130225566 Pharmaceutical combinations for the treatment of metabolic disorders
08/29/2013US20130225562 Pyridyltriazoles
08/29/2013US20130225560 Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors
08/29/2013US20130225559 S-mirtazapine for the treatment of hot flush
08/29/2013US20130225554 New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
08/29/2013US20130225551 Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
08/29/2013US20130225547 Proteasome inhibitors and uses thereof
08/29/2013US20130225546 Novel synthetic procedure and cancer treatment with cisplatin derivatives
08/29/2013US20130225544 Lipobalanced long chain testosterone esters for oral delivery
08/29/2013US20130225543 Specific regulation of cytokine levels by hdac6 inhibitors
08/29/2013US20130225542 Therapeutic Gestagens For The Treatment Of Premenstrual Dysphoric Disorder
08/29/2013US20130225540 Suppression of glial fibrillary acidic protein
08/29/2013US20130225537 Method for treating intestinal diseases presenting at least one inflammatory component
1 ... 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 ... 7860